Ghrelin在代谢性疾病中作用的研究进展

doi:10.16352/j.issn.1001-6325.2023.08.1299

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (8): 1299-1303.doi: 10.16352/j.issn.1001-6325.2023.08.1299

Ghrelin在代谢性疾病中作用的研究进展

王鑫瑞, 秦燕^*

大理大学基础医学院生理与病理生理学教研室,云南大理 671000

收稿日期:2022-07-21 修回日期:2022-12-04 出版日期:2023-08-05 发布日期:2023-07-26
通讯作者: ^*lantingxun@126.com
基金资助:
国家自然科学基金(81660111);大理大学创新团队建设项目(ZKLX2020306);云南省教育厅科学研究基金(2023Y0948); 云南省教育厅感染性疾病重点实验室建设项目子项目(DFYGR006)

Research advances of Ghrelin in metabolic diseases

WANG Xinrui, QIN Yan^*

Department of Physiology and Pathophysiology, School of Basic Medicine, Dali University, Dali 671000, China

Received:2022-07-21 Revised:2022-12-04 Online:2023-08-05 Published:2023-07-26
Contact: ^*lantingxun@126.com

摘要/Abstract

摘要： Ghrelin是一种新发现的胃源性肽,参与多种生物过程的调节。Ghrelin通过有效调控糖脂代谢、抗氧化等作用,在代谢性相关疾病如非酒精性脂肪性肝病、糖尿病、肥胖的发生发展中起重要作用。

关键词: Ghrelin, 非酒精性脂肪性肝病, 糖尿病, 肥胖

Abstract: Ghrelin, a newly discovered gastric peptide, involves in the regulation of various biological processes and plays important role in the occurrence and development of metabolic diseases such as non-alcoholic fatty liver disease, diabetes and obesity by effectively regulating glucose and lipid metabolism and anti-oxidation.

Key words: Ghrelin, non-alcoholic fatty liver disease, diabetes, obesity

中图分类号:

R589

王鑫瑞, 秦燕. Ghrelin在代谢性疾病中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1299-1303.

WANG Xinrui, QIN Yan. Research advances of Ghrelin in metabolic diseases[J]. Basic & Clinical Medicine, 2023, 43(8): 1299-1303.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.08.1299

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I8/1299

参考文献

[1]Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach[J]. Nature, 1999, 402: 656-660.
[2]Tong J, Dave N, Mugundu GM, et al. The pharmacokinetics of acyl, des-acyl, and total ghrelin in healthy human subjects[J]. Eur J Endocrinol, 2013, 168: 821-828.
[3]Yang Y, Liu R, Qu Y, et al. Ghrelin ameliorates transformation of hepatic ischemia-reperfusion injury to liver fibrosis by blocking Smad and ERK signalling pathways, and promoting anti-inflammation and anti-oxidation effects[J]. Transpl Immunol, 2022, 73: 101597. doi: 10.1016/j.trim.2022.101597.
[4]Vázquez MJ, Novelle MG, Rodríguez-Pacheco F, et al. AMPK-dependent mechanisms but not hypothalamic lipid signaling mediates GH-secretory responses to GHRH and Ghrelin[J]. Cells, 2020, 9. doi: 10.3390/cells9091940.
[5]Liu X, Guo Y, Li Z, et al. The role of acylated ghrelin and unacylated ghrelin in the blood and hypothalamus and their interaction with nonalcoholic fatty liver disease[J]. Iran J Basic Med Sci, 2020, 23: 1191-1196.
[6]Yin Y, Wang Q, Qi M, et al. Ghrelin ameliorates nonalcoholic steatohepatitis induced by chronic low-grade inflammation via blockade of Kupffer cell M1 polarization[J]. J Cell Physiol, 2021, 236: 5121-5133.
[7]Nagoya T, Kamimura K, Inoue R, et al. Ghrelin-insulin-like growth factor-1 axis is activated via autonomic neural circuits in the non-alcoholic fatty liver disease[J]. Neurogastroenterol Motil, 2020, 32: e13799. doi: 10.1111/nmo.13799.
[8]Alharbi S. Exogenous administration of unacylated ghrelin attenuates hepatic steatosis in high-fat diet-fed rats by modulating glucose homeostasis, lipogenesis, oxidative stress, and endoplasmic reticulum stress[J]. Biomed Pharmacother, 2022, 151: 113095. doi: 10.1016/j.biopha.2022.113095.
[9]Ezquerro S, Mocha F, Fruhbeck G, et al. Ghrelin reduces TNF-alpha-induced human hepatocyte apoptosis, autophagy, and pyroptosis: role in obesity-associated NAFLD[J]. J Clin Endocrinol Metab, 2019, 104: 21-37.
[10]Mao Y, Cheng J, Yu F, et al. Ghrelin attenuated lipotoxicity via autophagy induction and nuclear factor-kappaB inhibition[J]. Cell Physiol Biochem, 2015, 37: 563-576.
[11]Elabadlah H, Hameed R, D'Souza C, et al. Exogenous Ghrelin increases plasma insulin level in diabetic rats[J]. Biomolecules, 2020, 10. doi: 10.3390/biom10040633.
[12]Lindqvist A, Shcherbina L, Prasad RB, et al. Ghrelin suppresses insulin secretion in human islets and type 2 diabetes patients have diminished islet ghrelin cell number and lower plasma ghrelin levels[J]. Mol Cell Endocrinol, 2020, 511: 110835. doi: 10.1016/j.mce.2020.110835.
[13]Adriaenssens AE, Svendsen B, Lam BY, et al. Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets[J]. Diabetologia, 2016, 59: 2156-2165.
[14]Vestergaard ET, Jessen N, Moller N, et al. Acyl Ghrelin induces insulin resistance independently of GH, cortisol, and free fatty acids[J]. Sci Rep, 2017, 7: 42706. doi: 10.1038/srep42706.
[15]Lin Y, Liang Z, He L, et al. Gut Ghrelin regulates hepatic glucose production and insulin signaling via a gut-brain-liver pathway[J]. Cell Commun Signal, 2019, 17: 8. doi: 10.1186/s12964-019-0321-y.
[16]Yuan F, Zhang Q, Dong H, et al. Effects of des-acyl Ghrelin on insulin sensitivity and macrophage polarization in adipose tissue[J]. J Transl Int Med, 2021, 9: 84-97.
[17]白洁, 张锦妹, 刘丽苹, 等. 生长激素释放肽对糖尿病大鼠视网膜病变的保护作用[J]. 国际眼科杂志, 2021, 21: 1861-1864.
[18]Han W, Cui C, Zhang H, et al. Ghrelin ameliorates diabetes-associated behavioral deficits and NLRP3 inflammasome activation via autophagic flux enhancement[J]. Pharmacol Res, 2022, 179: 106224. doi: 10.1016/j.phrs.2022.106224.
[19]Atas U, Erin N, Tazegul G, et al. Changes in Ghrelin, substance P and vasoactive intestinal peptide levels in the gastroduodenal mucosa of patients with morbid obesity[J]. Neuropeptides, 2021, 89: 102164. doi: 10.1016/j.npep.2021.102164.
[20]Lee JH, Fang C, Li X, et al. GHS-R suppression in adipose tissues protects against obesity and insulin resistance by regulating adipose angiogenesis and fibrosis[J]. Int J Obes (Lond), 2021, 45: 1565-1575.
[21]Wasinski F, Barrile F, Pedroso JAB, et al. Ghrelin-induced food intake, but not GH secretion, requires the expression of the GH receptor in the brain of male mice[J]. Endocrinology, 2021, 162. doi:10.1210/endocr/bqab097.
[22]Hyland L, Park SB, Abdelaziz Y, et al. Ghrelin infused into the dorsomedial hypothalamus of male mice increases food intake and adiposity[J]. Physiol Behav, 2020, 220: 112882. doi: 10.1016/j.physbeh.2020.112882.
[23]Miao H, Pan H, Wang L, et al. Ghrelin promotes proliferation and inhibits differentiation of 3T3-L1 and human primary preadipocytes[J]. Front Physiol, 2019, 10: 1296. doi: 10.3389/fphys.2019.01296.
[24]Auclair N, Patey N, Melbouci L, et al. Acylated Ghrelin and the regulation of lipid metabolism in the intestine[J]. Sci Rep, 2019, 9: 17975. doi: 10.1038/s41598-019-54265-0.
[25]Péraldi-Roux S, Bayle M, M'Kadmi C, et al. Design and characterization of a triazole-based growth hormone secretagogue receptor modulator inhibiting the glucoregulatory and feeding actions of ghrelin[J]. Biochem Pharmacol, 2022, 202: 115114. doi: 10.1016/j.bcp.2022.115114.

Ghrelin在代谢性疾病中作用的研究进展

Research advances of Ghrelin in metabolic diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王丽婷, 许岭翎, 李伟, 平凡, 张化冰, 马亚红, 李玉秀. 不同亚型1型糖尿病患者大血管病变临床特征及危险因素分析[J]. 基础医学与临床, 2023, 43(8): 1284-1288.
[2]	吴智钢, 权冬, 常欣, 陈雪雪, 张子茹. 富血小板血浆加速糖尿病大鼠骨损伤愈合[J]. 基础医学与临床, 2023, 43(8): 1193-1200.
[3]	郝丹丹, 张垒, 白春英. 靶向铁死亡治疗非酒精性脂肪性肝病的研究进展[J]. 基础医学与临床, 2023, 43(8): 1317-1321.
[4]	刘充, 刘迎迎, 郭兆安. 特异性促炎消退介质在糖尿病肾脏疾病中的研究进展[J]. 基础医学与临床, 2023, 43(7): 1152-1156.
[5]	陈纤纤, 冯烈, 周颖, 董向楠. 糖尿病肾病与其他类型肾病患者肾组织中Smad1蛋白表达的比较[J]. 基础医学与临床, 2023, 43(7): 1097-1103.
[6]	张晶, 吴凯, 黄伟. 人前体脂肪细胞分化过程及肥胖人群脂肪组织中hsa_circ_0017650高表达[J]. 基础医学与临床, 2023, 43(7): 1079-1083.
[7]	周悦, 林静娜. miR-199-3p通过靶向VegfA抑制大鼠糖尿病视网膜病变[J]. 基础医学与临床, 2023, 43(7): 1084-1089.
[8]	蒋晨晨, 崔泽, 潘利, 孙纪新, 何慧婧, 胡耀达, 单广良. 河北省汉族和满族成人高血压家族史与超重/肥胖对高血压发病的交互作用[J]. 基础医学与临床, 2023, 43(7): 1053-1059.
[9]	余卓颖, 杨静, 蒋烨, 李民. 痛性及非痛性糖尿病神经病变的临床研究进展[J]. 基础医学与临床, 2023, 43(6): 985-989.
[10]	尹乐, 王丽妍, 黄红东. 复方α-酮酸对行腹膜透析的糖尿病患者生活质量和自我感受负担的影响[J]. 基础医学与临床, 2023, 43(5): 790-793.
[11]	舒玲, 霍本念, 宋林. NT5C2在疾病及治疗中的研究进展[J]. 基础医学与临床, 2023, 43(5): 852-856.
[12]	张梦瑶, 牛姝, 蔡静, 赵志刚, 周艳. miR-140-5p靶向HMGB1/IκB-α轴对糖尿病大鼠视网膜病变的影响[J]. 基础医学与临床, 2023, 43(4): 615-620.
[13]	蒋烨, 余卓颖, 李民. 炎性反应在糖尿病神经病变发生中作用的研究进展[J]. 基础医学与临床, 2023, 43(4): 669-673.
[14]	张艺馨, 蔡善君, 李智立, 于伟泓, 张华. IgG N-糖基化修饰在糖尿病视网膜病变中作用的研究进展[J]. 基础医学与临床, 2023, 43(3): 509-513.
[15]	邹洁, 张德德, 陶毅, 赵静, 王琼, 徐乃佳. 葛根素减轻KKAy小鼠血管内皮细胞炎性反应[J]. 基础医学与临床, 2023, 43(3): 433-437.